NEW YORK – November 26, 2025
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present one oral late breaking communication and two poster presentations featuring blarcamesine at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, being held in San Diego, California from December 1–4, 2025.
Details:
Presentation #1 (LB11)
- Title: Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer’s Disease Patients
- Presenter: Marwan Noel Sabbagh, MD, Professor of Neurology, and Chairman of the Anavex Scientific Advisory Board
- Time: December 2, 4:35 pm PT – 4:50 pm PT
Presentation #2 (P076)
- Title: Oral Blarcamesine Comparison to Normal Cognitive Aging: Demonstrating Alignment with Prodromal Cognitive Aging Trajectories in Precision Medicine Patient Population Phase IIb/III Trial – for Early Alzheimer’s Disease Patients
- Presenter: Audrey Gabelle, MD, PhD, Professor of Neurology, Neurologist, Member of the Anavex Scientific Advisory Board and Doctor of Neurosciences at Montpellier University
- Time: December 1, 3:00 pm PT – December 2, 5:30 pm PT
Presentation #3 (P084)
- Title: Advancing Alzheimer’s Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine
- Presenter: Marwan Noel Sabbagh, MD, Professor of Neurology, and Chairman of the Anavex Scientific Advisory Board
- Time: December 1, 3:00 pm PT – December 2, 5:30 pm PT
“We are excited to present, backed up by published clinical data, oral, once daily blarcamesine with its upstream mechanism of action restoring autophagy — the key driver in restoring cellular homeostasis — which could be essential to treating Alzheimer’s by activating the brain’s recycling process, which is impaired in Alzheimer’s disease. Blarcamesine demonstrated in early Alzheimer’s disease patients clinically meaningful effects of slowing cognitive decline with an adequate safety profile (no ARIA) as demonstrated in the Phase IIb/III program,” said Marwan Noel Sabbagh, MD. “Additionally, our steadfast focus is on driving progress in Alzheimer’s disease development and providing meaningful options to improve the lives of patients and those who care for them.”
This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.
About The 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
The Clinical Trials on Alzheimer’s Disease (CTAD) Conference, established in 2008, has become a cornerstone event in Alzheimer’s disease (AD) clinical research. Designed by and for AD researchers, CTAD’s mission is to create a platform that prioritizes substantive, clinical research-focused dialogue and collaboration, fostering collaborations and advancing the global AD research agenda.
The 18th annual CTAD Conference (CTAD25) will be held in San Diego, CA, on December 1–4, 2025. CTAD25 will highlight rapid advancements in AD diagnostics and therapeutics, a reflection of the dynamic progress within the field.
CTAD25 also features symposia and roundtables exploring the latest developments across disease-modifying agents, gene therapy, vaccines, multimodal interventions, and more. A rigorous peer-review abstract process ensures the presentation of high-quality research.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, Rett syndrome, and other CNS diseases. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), has completed clinical trials in Alzheimer’s disease, Parkinson’s disease dementia, and Rett syndrome. Further information is available at www.anavex.com, and the Company can be found on Twitter, Facebook, Instagram, and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly historical are forward-looking statements based on current information and expectations. Actual results may differ materially due to various risks, including those described in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers should not place undue reliance on forward-looking statements. Anavex undertakes no obligation to update forward-looking statements to reflect future events.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com